TY - JOUR
T1 - Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials
T2 - Perspectives of people who inject drugs
AU - Park, Ju Nyeong
AU - White, Bethany
AU - Bates, Anna
AU - Enriquez, Jarliene
AU - Liao, Len
AU - Maher, Lisa
N1 - Funding Information:
Funding for this study was provided by the National Health and Medical Research Council (NHMRC) (Grant number 630483 : Hepatitis C Vaccine Preparedness Study). Bethany White is supported by an NHMRC Dora Lush postgraduate research Scholarship . Lisa Maher is supported by the award of a NHMRC Senior Research Fellowship . The NHMRC had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The Kirby Institute is affiliated with the Faculty of Medicine, University of New South Wales and is funded by the Australian Government Department of Health and Ageing . The views expressed here do not necessarily represent the position of the Australian Government.
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/6/1
Y1 - 2012/6/1
N2 - Background: A safe and efficacious vaccine may be the most efficient and cost-effective strategy for controlling the hepatitis C virus (HCV) epidemic among people who inject drugs (PWID) and several candidates are in development. However, little is known about the factors that influence willingness to participate (WTP) in candidate HCV vaccine trials among this group. Methods: HCV seronegative PWID recruited between 2008 and 2010 as part of a prospective observational cohort study in Sydney, Australia were asked whether they would be willing to participate in a future candidate hepatitis C vaccine trial and to provide reasons to explain their decision. Results: Of 113 participants, 74% indicated WTP, 15% were unwilling to participate and 11% reported WTP that was contingent on vaccine characteristics and trial design issues. The most commonly reported motivator for hypothetical trial participation was altruism, followed by potential health benefits, financial remuneration, and knowledge gain. Barriers to hypothetical participation included fears about possible harms to health, such as concerns about vaccine safety, side effects, and acquiring HCV from the vaccine; other barriers included mistrust of biomedical research and time constraints. Conclusions: These results may be useful in designing strategies to enhance HCV vaccine trial recruitment and retention and have ethical implications for developing informed consent processes and standards of care.
AB - Background: A safe and efficacious vaccine may be the most efficient and cost-effective strategy for controlling the hepatitis C virus (HCV) epidemic among people who inject drugs (PWID) and several candidates are in development. However, little is known about the factors that influence willingness to participate (WTP) in candidate HCV vaccine trials among this group. Methods: HCV seronegative PWID recruited between 2008 and 2010 as part of a prospective observational cohort study in Sydney, Australia were asked whether they would be willing to participate in a future candidate hepatitis C vaccine trial and to provide reasons to explain their decision. Results: Of 113 participants, 74% indicated WTP, 15% were unwilling to participate and 11% reported WTP that was contingent on vaccine characteristics and trial design issues. The most commonly reported motivator for hypothetical trial participation was altruism, followed by potential health benefits, financial remuneration, and knowledge gain. Barriers to hypothetical participation included fears about possible harms to health, such as concerns about vaccine safety, side effects, and acquiring HCV from the vaccine; other barriers included mistrust of biomedical research and time constraints. Conclusions: These results may be useful in designing strategies to enhance HCV vaccine trial recruitment and retention and have ethical implications for developing informed consent processes and standards of care.
KW - Clinical trial
KW - Hepatitis c virus
KW - Injecting drug use
KW - Vaccine
KW - Willingness to participate
UR - http://www.scopus.com/inward/record.url?scp=84861220848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861220848&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2011.10.009
DO - 10.1016/j.drugalcdep.2011.10.009
M3 - Article
C2 - 22071117
AN - SCOPUS:84861220848
SN - 0376-8716
VL - 123
SP - 35
EP - 40
JO - Drug and alcohol dependence
JF - Drug and alcohol dependence
IS - 1-3
ER -